Comment by pen2l

Pasting from linked twitter thread, while this is encouraging, some things are left to be desired:

1) No data for the most vulnerable older (>55) population

2) Second dose absolutely necessary

3) Safety profile less than desirable

4) Durability of neutralizing Ab not so encouraging (decline from day 43~57)

5) Very low CD8 T-cell responses

Novavas phase I results (NVX-CoV2373), probably due to be out soon, will be interesting.